Advanced Esophageal Cancer in Patients who Underwent Radiofrequency Ablation for Barrett Esophagus with High-Grade Dysplasia

Author(s):  
Min P. Kim ◽  
Kendra N. Brown ◽  
Mary R. Schwartz ◽  
Shanda H. Blackmon
Author(s):  
Min P. Kim ◽  
Kendra N. Brown ◽  
Mary R. Schwartz ◽  
Shanda H. Blackmon

Objective We sought to evaluate clinicopathologic features of patients who underwent esophageal surgery after radiofrequency ablation (RFA) treatment using the HALO system for Barrett esophagus (BE) with high-grade dysplasia (HGD). Methods We evaluated patients from our hospital database who underwent esophagectomy from August 2006 to January 2012 after previously receiving RFA for BE. Information on demographics, time between RFA and surgery, indications for surgery, and final esophageal pathology was collected. Results In our study, we selected 102 patients who underwent esophagectomy. Five patients had a history of RFA for BE with HGD. Three patients were referred because of persistent HGD despite RFA, and all three patients had HGD in the esophagectomy specimen. Two patients presented with a benign diagnosis (esophageal perforation and leiomyoma), and both of these patients had pathologic stage T3N2M0 adenocarcinoma of the esophagus in the resected specimen. One of these patients had normal mucosa overlying carcinoma in the muscularis propria and adventitia. The patients with stage T3N2M0 cancer did not have pre-RFA endoscopic ultrasound, first treatment of RFA with HALO360, or surveillance endoscopic biopsy every 3 months. Conclusions Radiofrequency ablation for BE with HGD may mask underlying esophageal cancer. Patients who are counseled to undergo RFA for HGD should be aware that RFA could lead to delayed diagnosis and delayed treatment of invasive esophageal cancer without careful patient selection, appropriate RFA use, and close surveillance.


2009 ◽  
Vol 69 (5) ◽  
pp. AB345-AB346
Author(s):  
Roos E. Pouw ◽  
Frederike G. Van Vilsteren ◽  
Lorenza Alvarez Herrero ◽  
Joep J. Gondrie ◽  
Carine Sondermeijer ◽  
...  

2009 ◽  
Vol 69 (5) ◽  
pp. AB133-AB134 ◽  
Author(s):  
Frederike G. Van Vilsteren ◽  
Roos E. Pouw ◽  
Stefan Seewald ◽  
Lorenza Alvarez Herrero ◽  
Carine Sondermeijer ◽  
...  

2010 ◽  
Vol 134 (10) ◽  
pp. 1479-1484 ◽  
Author(s):  
John R. Goldblum

Abstract Context.—Pathologists frequently assess esophageal biopsy specimens to “rule out Barrett esophagus,” as well as to assess for the presence or absence of dysplasia. Objective.—To review some of the recent controversies in the diagnosis of Barrett esophagus and Barrett-related dysplasia. Data Sources.—Sources were the author's experience and review of the English literature from 1978 to 2009. Conclusions.—Although goblet cells are required by the American College of Gastroenterology to confirm a diagnosis of Barrett esophagus, this definition might expand to include columnar-lined esophagus without goblet cells. The recognition of dysplasia in Barrett esophagus remains a difficult task for the surgical pathologist, with difficulties in distinguishing reactive epithelium from dysplasia, low-grade dysplasia from high-grade dysplasia, and even high-grade dysplasia from intramucosal adenocarcinoma.


2009 ◽  
Vol 69 (5) ◽  
pp. AB255
Author(s):  
Jason M. Dunn ◽  
Sally Thorpe ◽  
Marco Novelli ◽  
Stephen G. Bown ◽  
Laurence Lovat

2007 ◽  
Vol 65 (5) ◽  
pp. AB151 ◽  
Author(s):  
Joep J. Gondrie ◽  
Roos E. Pouw ◽  
Carine Sondermeijer ◽  
Wilda D. Rosmolen ◽  
Femke Peters ◽  
...  

2019 ◽  
Vol 52 (3) ◽  
pp. 269-272 ◽  
Author(s):  
Joana Castela ◽  
Miguel Serrano ◽  
Susana Mão de Ferro ◽  
Daniela Vinha Pereira ◽  
Paula Chaves ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document